Prescient Therapeutics opens $7 million share purchase plan to advance PTX-100
Kort samengevat
Prescient Therapeutics Ltd (ASX:PTX) has opened its share purchase plan (SPP) targeting up to $7 million to help advance its lead cancer therapy PTX-100 through its ongoing Phase 2a clinical program.
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij Proactiveinvestors UK.
Lees het volledige bericht ↗